Feeding and eating disorders in the DSM-5 era: a systematic review of prevalence rates in non-clinical male and female samples

Camilla Lindvall Dahlgren1*, Line Wisting1 and Øyvind Rø1,2

Abstract

Objective: The objective of this study was to systematically review the literature on the prevalence of eating disorders (EDs) during the DSM-5 era, and to report rates of point- and lifetime prevalence.

Method: A PubMed search was conducted targeting articles on the epidemiology of EDs, in particular, reported rates of prevalence. The review was performed in accordance with PRISMA guidelines, and was limited to DSM-5 based eating disorder diagnoses published between 2012 and 2017.

Results: A total of 19 studies fulfilled inclusion criteria and were included in the study.

Discussion: Following the transition to DSM-5, it is evident that the prevalence of eating disorder not otherwise specified (EDNOS)/other specified feeding and eating disorders (OSFED) has decreased as intended, and there is preliminary evidence suggesting that rates of anorexia nervosa (AN) and bulimia nervosa (BN) and binge eating disorder (BED) have increased. Further, we observed higher rates of BED prevalence among females compared to males, with rates increasing with age. A limitation to the study was the search date, and that none of the included studies investigated the "new" DSM-5 feeding disorders avoidant restrictive food intake disorder (ARFID), pica or rumination disorder warranting attention in future studies investigating the epidemiology of feeding and eating disorders.

Keywords: Epidemiology, Prevalence, Eating disorders, DSM-5, Systematic review

Plain English summary

The aim of writing this literature review was to provide the reader with an overview of published studies using the newest version of the Diagnostic and Statistical Manual of Mental Disorders, the DSM-5, in assessing eating disorder prevalence. A literature search was performed in accordance with well established guidelines, resulting in 19 studies fulfilling inclusion criteria. As intended, rates of the residual eating disorder category “other specified feeding and eating disorders” had increased, and preliminary evidence supported increased prevalence of anorexia nervosa, bulimia nervosa and binge eating disorder. No studies assessing the prevalence of feeding disorders (i.e. Pica, Rumination Disorder and Avoidant Restrictive Food Intake Disorders) were identified.

Background

In 2013, the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) [1] was replaced by its successor, the DSM-5 [2], yielding a number of adjustments in diagnostic criteria across psychiatric diagnoses. For eating disorders (ED) in specific, a main intention of the DSM-5 adjustments was to decrease the number of ED cases falling into the former diagnostic category “eating disorder not otherwise specified” (EDNOS), a poorly defined and heterogeneous residual category representing the majority of DSM-IV ED cases. This was done by removing binge eating disorder (BED) from the DSM-IV EDNOS category, and reintroducing it as an independent and specified DSM-5 diagnosis, and by expanding the boundaries of anorexia nervosa (AN) and bulimia nervosa (BN). The DSM-5 retained practically all core AN features, but clarified the weight criteria by changing the wording from “a body weight less than 85% of that expected” to “significantly low weight”. Also,
the amenorrhea criterion was removed. For BN, the minimum frequency of binge eating episodes and inappropriate compensatory behavior was reduced from twice a week to once a week. In addition to these changes, three disorders previously reserved for children and classified as ‘Feeding and Eating Disorders of Infancy or Early Childhood’ were revised and introduced in the DSM-5 as independent diagnostic categories: pica, avoidant/restrictive food intake disorder (ARFID) and rumination disorder. Finally, EDNOS was replaced by other specified feeding and eating disorders (OSFED) including atypical AN, subthreshold BN and subthreshold BED, purging disorder (PD), night eating syndrome (NES), as well as unspecified feeding and eating disorders (UFED) representing cases where behaviors cause clinically significant distress/impairment of functioning, but fail to meet full criteria for a feeding or eating disorder.

In the years to come, the new diagnostic criteria for EDs are likely to yield alterations in reported point (proportion of individuals affected by a disorder at the one specific point in time) and lifetime (proportion of individuals having been affected by a disorder at any time in life up to the measurement point) prevalence rates. Historically, ED prevalence rates reported using the DSM-IV have varied considerably across studies, with discrepancies being a result of a number of methodological issues such as inconsistent use of assessment instruments [3], variations in study designs [4] and estimates calculated using non-representative samples [5]. It is therefore important to assess trends in occurrence rates on a regular basis, taking into account changes to diagnostic criteria as well as methodological aspects influencing observed trends.

Following the transition from DSM-IV to DSM-5, it is relevant to review whether the revisions to the DSM-IV have resulted in alterations in diagnostic distribution, and to identify diagnostic categories in need of further research. Four years into the DSM-5 era, a small number of studies do, in fact, show that the new diagnostic system alters the representation and distribution of ED diagnoses with evidence of increased lifetime prevalence of BN and BED [6] and increased lifetime [7] and point prevalence [8] of AN. Further, reduced numbers of identified OSFED and UFED cases [9–11] have also been reported. However, only a limited number of studies have sought to investigate the prevalence of DSM-5 feeding disorders (i.e. pica, ARFID and rumination disorder), or the occurrence of the OSFED categories such as subclinical AN, BN and BED, as well as NES and PD. In sum, there have been important recent developments that warrant further attention. These includes the emergence of new empirical findings from studies assessing ED prevalence using DSM-5 criteria, as well as findings from retrospective studies recoding DSM-IV diagnoses into new DSM-5 ED categories. The aim of this study was to systematically review the field for studies reporting ED prevalence based on DSM-5 criteria in non-clinical female and male samples. The review was performed according to PRISMA guidelines [12] and synthesized studies published between 2012 and 2017.

**Methods**

**Search strategy**

The literature was reviewed in February 2017, using the PubMed search below. The screening process was conducted according to the criteria outlined by the PRISMA guidelines, and is presented in Fig. 1.

```
((((((((anorexia[All Fields] AND nervosa[All Fields]) AND DSM-5[All Fields] AND prevalence[All Fields]) OR ((bulimia[All Fields] AND nervosa[All Fields]) AND DSM-5[All Fields] AND prevalence[All Fields]))) OR (eating[All Fields] AND disorder[All Fields]) AND DSM-5[All Fields] AND prevalence[All Fields]))) OR (binge[All Fields] AND eating[All Fields] AND disorder[All Fields]) AND DSM-5[All Fields] AND prevalence[All Fields]))) OR (avoidant[All Fields] AND restrictive[All Fields]) AND DSM-5[All Fields] AND prevalence[All Fields])) OR (PICA[All Fields] AND DSM-5[All Fields] AND prevalence[All Fields])) OR (OSFED[All Fields] AND DSM-5[All Fields] AND prevalence[All Fields])) OR (rumination[All Fields] AND disorder[All Fields]) AND DSM-5[All Fields] AND prevalence[All Fields])) OR (food[All Fields] AND intake[All Fields] AND DSM-5[All Fields] AND prevalence[All Fields]))
```

**Eligibility criteria**

Publications were targeted that examined the epidemiology of EDs, in particular ED prevalence rates, in non-clinical samples, and were selected for review according to the criteria outlined below.

A. Articles that presented ED prevalence rates based on DSM-5 criteria (articles presenting recoded diagnostic categories (e.g. from DSM-IV to DSM-5) were also eligible)

B. Articles that were written in English or had an available published English translation

C. Articles that were published in peer reviewed journals

**Exclusion criteria**

All papers investigating ED prevalence in clinical samples were excluded. Editorials, commentaries, systematic reviews, as well as articles reporting prevalence of disordered eating without utilizing DSM-5 ED diagnoses (e.g. ED features or syndromes) were omitted. Exclusions were tracked and registered (see Fig. 1). Omitted review
Title, abstract and article selection
Publication titles in studies obtained through the search strategy outlined earlier were reviewed by the authors CLD and LW. All titles clearly irrelevant to the aim and scope of the paper (e.g. “Food addiction – substance use disorder or behavioral addiction”) were excluded during this initial screening. Publications with ambiguous titles (e.g. “Eating disorders in older women”) and publications with titles clearly relevant to the aim of the paper (e.g. “Prevalence and severity of DSM-5 eating disorders in a community cohort of adolescents”) were included at this stage of the screening process. Abstracts were then screened by CLD and LW using a similar strategy (i.e. screening for irrelevance, ambiguity and certainty), after which full texts were retrieved and assessed for eligibility by CLD and LW using the outlined eligibility and exclusion criteria. Agreement was reached for all included and excluded publications. None of the reviewers were blind to the authors of the texts, nor their affiliations.

Results
Search summary
The PubMed search strategy produced 94 titles, which after the initial title screen was reduced to 43. Of these 43, 21 were omitted in the abstract screening process. A total of 22 papers met eligibility criteria and were retained. Subsequently, three full-text studies were excluded based on lack of relevance, leading to a total inclusion of 19 studies. No additional studies were found through the screening of review articles. A more detailed overview of the screening process is presented in Fig. 1.
Table 1 summarizes all included studies. No studies meeting eligibility criteria were published before 2012. Assessments of the following full- and subthreshold diagnoses were reported: ED, AN, BN, BED, OSFED and UFED. OSFED included atypical AN (OSFED-AN) subthreshold BN (OSFED-BN) and subthreshold BED (OSFED-BED), as well as purging disorder (OSFED-PD) and night eating syndrome (OSFED-NES). No studies reporting ARFID, rumination disorder or Pica were identified.

The majority of included studies presented data from US samples (N = 5), closely followed by Australia (N = 3), Germany (N = 2), Finland (N = 2) and Canada (N = 2). Portugal, Sweden, United Kingdom, Switzerland and the Netherlands all represented one individual study. Ages ranged from 11 to 96, with eight studies reporting data from adults only (>18), nine studies reporting rates from mixed age samples (i.e. children, adolescents and adults) and two studies presented data collected in samples below the age of 15. Sample sizes ranged from 496 to 22,397, and approximately 25% (N = 5) of the included studies followed a two-stage design approach in estimating ED prevalence. Six studies used interviews alone to establish ED diagnoses, and seven studies employed self-reports. Trace et al. [6] did not specify the design of the study. Disregarding prevalence reports using data from overlapping samples [7, 10, 13, 14], all studies employing 2-stage designs had used different screening instruments.

Prevalence rates

In 2-stage design studies, lifetime AN prevalence rates in females ranged from 1.7% [15] to 3.6% [9], and point prevalence ranged from 0.67% [9] to 1.2% [15]. Only one study reported male AN prevalence and they found both point and lifetime to be 0.1% [15]. BN was most commonly assessed using point prevalence, but was only assessed in two out the five 2-stage design studies [9, 15]. These studies reported nearly identical point BN prevalence rates of 0.59% and 0.6% respectively in females. Point prevalence rates for BED were reported in three studies, and ranged from 0.62% [9] (females only) to 3.6% [16] (males and females combined). Lifetime prevalence rates for OSFED ranged from 0.3% in males [15] to 0.6% in females [10] and point prevalence from 0.0% in males [15] to 2.4% in a sample combining male and females rates. Lifetime prevalence rates of UFED in females were 0.2% [15] and 0.9% [10] respectively.

In interview based studies, lifetime prevalence of AN in females ranged from 0.8% [17] to 1.9% [4]. Lifetime BN prevalence in females of was only reported in one of these studies, with a rate of 2.6% [17]. In two out of the six interview-based studies, lifetime rates of BED were reported. BED in females were 3.0% [17] and 3.6% [18] respectively, whereas the corresponding rates for males were only assessed in one study [18] reporting a rate of 2.1%. In females prevalence of OSFED was reported in the interview based prevalence studies, with overall OSFED point prevalence rates ranging from 5% [19] to lifetime prevalence rate of 11% [17].

Point prevalence was most commonly reported in studies using the self-report design. Here, AN rates ranged from 0.06% [14] to 1.2% in females [15]. BN prevalence rates ranged from 0.45% [11] to 8.7% in females [20]. BED rates ranged from 0.0% (in males) [20] to 4.1% (in females). Two studies [21, 22] set out to investigate the occurrence of night eating syndrome (NES). In these studies, point prevalence was established using the Night Eating Questionnaire (NEQ) [23] and a brief version of the Eating Disorder Examination Questionnaire, the EDE-Q8 [24]. Rates reported for both genders were 1.1% and 4.2% respectively.

Discussion

The current study reviewed the prevalence of DSM-5 eating disorders. A total of 19 studies were identified in our literature search, with results showing substantial variability in prevalence rates. A wide range of both point- and lifetime prevalence rates were reported across included studies, with variance being dependent on, first and foremost, the methodologies applied.

As intended, a number of studies now support the decline in EDNOS/OSFED prevalence following the DSM-5 diagnostic revision intention [10, 11]. Decreased EDNOS/OSFED prevalence has also been reported in studies having recoded ED diagnoses [9, 13, 20]. However, although the introduction of the new DSM-5 criteria appears to have resolved some of the challenges associated with EDNOS, OSFED still represents a heterogeneous group in the DSM-5, including a variety of different ED conditions. For example, PD, which has been shown to be associated with significant medical complications [25], was investigated specifically in three studies in our review [11, 14, 26]. Prevalence rates ranged from 0.58% (CI 0.42-0.80) – 3.77% (CI 3.14-4.49) with results illustrating a trend towards higher rates in females compared to males, as well higher rates in adults compared to adolescents. However, it should be noted that lifetime prevalence rates as opposed to point prevalence rates, in general, is expected to be higher, especially when assessed in older populations. Night eating syndrome (NES) was also included in the DSM-5 OSFED category, and specifically assessed in two of the reviewed studies. [21, 22] Both adopted the self-report measure Night Eating Questionnaire (NEQ) [23]. Whereas de Zwaan and colleagues [23] reported a point prevalence of 1.1% among males and females aged 14-85 years (mean age 48), Runfola et al. [24] reported a prevalence of 4.2 among males and females aged 18-26 years (mean age 21). These discrepant findings in
Table 1 Overview of included studies published 2012-2017. Studies are grouped by design and listed in chronological order.

| Author (Year) | N  | Country | Gender | Age range | Sample | Assessment | Prevalence type | Prevalence (%) of ED, AN, BN (95% CI) | Prevalence (%) of BED, OSFED, UFED (95% CI) |
|---------------|----|---------|--------|-----------|--------|------------|-----------------|--------------------------------------|---------------------------------------------|
| **2-STAGE DESIGN** | | | | | | | | | |
| Mustelin et al. [10]^a | 2825 | Finland | ♀ | 22-27 | FinnTwin16 sample | Screening: Self-report questionnaire developed for the study and three subscales from the EDI-2 | Diagnosis: SCID-I/NP | Lifetime | NR | OSFED + UFED: 1.5 (1.1-2.1) |
| | | | | 24.4 (0.8) | | | | | | OSFED: 0.6 (0.3-1.0) |
| | | | | | | | | | | UFED: 0.9 (0.6-1.4) |
| Mustelin et al. [7]^b | 2825 | Finland | ♀ | 22-27 | FinnTwin16 sample | Screening: Self-report questionnaire developed for the study and three subscales from the EDI-2 | Diagnosis: SCID-I/NP | Lifetime | AN: 3.6 (2.7-4.2) | NR | |
| | | | | 24.4 (0.8) | | | | | | |
| | | | | | | | | | | |
| Salimi et al. [16]^c | 1698 | UK | ♀ | 16-90 | SELCoH | Screening: SCOFF | Diagnosis: SCID-I/NP | Point | ED: 7.4 (4.1-13.0) | BED: 3.6 (1.4-9.0) |
| | | | | (mean and SD not available) | | | | AN: 0.0 (0) | OSFED: 2.4 (0.9-6.7) |
| | | | | | | | | BN: 0.8 (0.4-1.8) | OSFED-PD: 0.6 (0.2-1.5%) |
| | | | | | | | | | | |
| Smink et al. [15]^d | 1597 | Holland | ♀ | 19.1 (0.6) | Community cohort | Screening: Questionnaire on mental health and social functioning, height/weight and WHO-CIDI | Diagnosis: SCID-I and parts of EDE | Lifetime (L) | Point (P) | BED (L, P): 2.3, 1.6 (1.4-3.6, 0.9-2.7) |
| | | | | (age range not available) | | | | | | OSFED (L, P): 0.6, 0.3 (0.2-1.3, 0.1-1.0) |
| | | | | | | | | | | UFED (L, P): 0.2, 0.0 (0.0-0.8, 0) |
| | | | | | | | | | | |
| Machado et al. [9] | 3048 | Portugal | ♀ | 12-23 | Female high-school and university students | Screening: EDE-Q | Diagnosis: EDE | Point | ED: 3.87 (CI NR) | BED: 0.62 (CI NR) |
| | | | | 16.2 (1.3) | | | | AN: 0.69 (CI NR) | EDNOS: 1.97 (CI NR) |
| | | | | 18-58 | | | | BN: 0.59 (CI NR) | |
| | | | | 21.8 (4.3) | | | | | | |
| | | | | | | | | | | |
| **INTERVIEW** | | | | | | | | | |
| Mohler-Kuo et al. [4]^e | 10,038 | Switzerland | ♀ | 15-60 | Household survey | WHO-CIDI | Lifetime (L) | 12-month (12-m) | AN (L, 12-m): 1.9, 0.07 (1.6-2.3, 0.03-0.2) |
| | | | | (mean and SD not available) | | | | AN (L, 1.2-m): 0.2, 0.03 (0.1-0.4, 0.004-0.2) | BED (L, P): 2.3, 1.6 (1.4-3.6, 0.9-2.7) |
| | | | | | | | | | | OSFED (L, P): 0.6, 0.3 (0.2-1.3, 0.1-1.0) |
| | | | | | | | | | | UFED (L, P): 0.2, 0.0 (0.0-0.8, 0) |
| | | | | | | | | | | |
| Hay et al. [11]^f | 6041 | Australia | ♀ | 15-96 | Cross sectional population sample. | Items based on diagnostic items from the EDE | Point (3-month) | Total sample (% females): | ED: 10.7 (5.7-15.7) |
| | | | | (mean and SD not available) | | | | AN: 0.46 (43%) (0.32-0.67) |
| | | | | | | | | | BN: 0.66 (69%) (0.49-0.9) | OSFED-BN: 0.70 (74%) (0.51-0.94) |
| | | | | | | | | | | OSFED-BED: 0.6 (55%) (6.31-7.59) |
| | | | | | | | | | | EDNOS: 0.6 (0.2-1.6) |
| | | | | | | | | | | UFED: 1.4 (73%) (1.14-1.74) |
| | | | | | | | | | | |
| Munn-Chernoff et al. [20]^g | 3230 | USA | ♀ | 18-29 | Median: 22 (mean and SD not available) | Population-based twin study | Adapted version of SSAGA | Lifetime | AN: 1.37 (1.00-1.84) | OSFED-PD: 3.77 (3.14-4.49) |
| | | | | | | | | | | |
| | | | | | | | | | | |
| Fairweather-Smith & Wade [19]^h | 699 | Australia | ♀ | 12-21 | Adolescent female twin pairs | EDE | Calculated a total prevalence rate based on wave 1-3 | ED: 10.4 (8.3-12.9) |
| | | | | | | | | | AN: 2.5 (CI NR) |
| | | | | | | | | | BN: 1.0 (CI NR) | BED: 2.4 (CI NR) |
| | | | | | | | | | | OSFED: 5.0 (CI NR) |
| | | | | | | | | | | OSFED-AN: 19 (CI NR) |
| | | | | | | | | | | OSFED-BN2: 26 (CI NR) |
| | | | | | | | | | | OSFED-PD: 0.6 (CI NR) |
| | | | | | | | | | | |
| Slice et al. [17]^i | 496 | USA | ♀ | 12-15 | Baseline: Mean = 13 (SD not available) | Community sample | EDDI | Lifetime (L) | AN: 0.8 (± 0.6) |
| | | | | | | | | | BN: 2.6 (± 1.4) | BED: 3.0 (± 1.3) |
| | | | | | | | | | | OSFED: 11.5 (± 2.8) |
| | | | | | | | | | | OSFED-AN: 28 (± 1.5) |
| | | | | | | | | | | OSFED-BN: 4.4 (± 1.6) |
Table 1 Overview of included studies published 2012-2017. Studies are grouped by design and listed in chronological order (Continued)

| Author          | N     | Country | Gender (N or %) | Age range | Sample Assessment | Prevalence type | Prevalence (%) of ED, AN, BN (95% CI) | Prevalence (%) of BED, OSFED, UFED (95% CI) |
|-----------------|-------|---------|-----------------|-----------|-------------------|----------------|---------------------------------------|---------------------------------------------|
| Hudson et al.   | 888   | USA     | ♀ (66.4%)       | 18-70     | First-degree relatives of probands with or without BED | SCID           | Lifetime (L)                          | NR                                         |
|                 |       |         | ♂ (33.6%)       | 46.7 (17.4) |                    |                | Point (P)                             | BED ♂ (L, P): 3.6, 1.7 (CI NR)              |
| Self-report     |       |         |                 |           |                   |                |                                       | BED ♂ (L, P): 2.1, 0.8 (CI NR)              |
| Cossrow et al.  | 22,397| USA     | ♀ (54.4%)       | ≥18       | Questions assessing BED criteria through a self-administered Internet survey | Life-time (L) 3-month (3-m) 12-month (12-m) | NR | BED ♂ + ♀ (L, 3-m, 12-m): 2.03, 1.19, 1.64 (1.83-2.26, 1.04-1.37, 1.45-1.85) |
|                 |       |         | ♂ (45.6%)       | (age range not available) |                   |                |                                       | BED ♂ + ♀: 2.1, 1.3, 1.2 (0.96-2.64)    |
|                 |       |         |                 |           |                   |                |                                       | OSFED-BED: 3.6 (± 1.5) OSFED-PD: 3.4 (± 1.6) |
| Hammerle et al. | 1654  | Germany | ♀ (N = 873)     | 13.4 (0.8) | National school-based cross-sectional survey | SIAB-S (as questionnaire) and EDI-2 | Point | Full syndrome (sex ratio female-male) |
|                 |       |         | ♂ (N = 781)     | (age range not available) |                   |                |                                       | OSFED-BED: 1.1 (CI NR) |
| Flament et al.  | 3043  | Canada  | ♀ (N = 4126)    | 11-21     | Community sample | EDDS           | Point | ED (♀, ♂): 4.46, 2.21 (4.4-4.5, 1.5-3.2) |
|                 |       |         | ♂ (N = 5886)    | 14.2 (1.6) |                    |                |                                       | AN (♀, ♂): 0.14, 0.06 (0.01-0.17, 0.05-0.23) |
|                 |       |         |                 |           |                   |                |                                       | BN (♀, ♂): 0.37, 0.26 (0.20-0.56, 0.18-0.44) |
|                 |       |         |                 |           |                   |                |                                       | OSFED-BED: 0.0 (0.0-0.1) OSFED-PD: 0.1 (0.0-0.2) |
|                 |       |         |                 |           |                   |                |                                       | OSFED-BED: 1.5 (1.3-1.7) OSFED-PD: 1.4 (1.2-1.6) |
| de Zwaan et al. | 2460  | Germany | ♀ (51.1%)       | 14-85     | Population sample | NEQ and EDE-Q8 | Point | NR | OSFED-NES: 1.1 (CI NR) |
|                 |       |         | ♂ (48.9%)       | 48.1 (19.0) |                   |                |                                       | |
| Runfola et al.  | 1636  | USA     | ♀ (59.5%)       | 18-26     | University students | An online survey using the NEQ | Point | NR | OSFED-NES: 4.2 (CI NR) |
|                 |       |         | ♂ (40.5%)       | 20.9 (1.7) |                    |                |                                       | |
| Allen et al.    | 1383  | Australia | ♀ (49%)        | 14-20     | Prospective, population-based cohort study | CHEDE and the EDE-Q | Point | ED (♀, ♂): 14-yrs: 8.5, 1.2 (14-20 years: 14.0 (0.2) |
|                 |       |         | ♂ (51%)        | 17-years: 16.9 (0.2) 20-years: 20.0 (0.4) |                    |                |                                       | |

Lindvall Dahlgren et al. Journal of Eating Disorders (2017) 5:56 Page 6 of 10
prevalence may relate to the differences in age between the two samples, but more research is warranted to investigate this further. Additionally, the new category Unspecified Feeding or Eating Disorder (UFED) was introduced in the DSM-5. UFED is used to describe symptoms characteristic of feeding or eating disorders causing significant stress or impairments in functioning, but without meeting full criteria for an ED diagnosis. The UFED category can be used when reasons for not meeting full criteria is lacking or not further specified by clinicians. Three of the included studies [10, 11, 15] reported prevalence of UFED, with rates ranging from 0.0% to 1.41%. Further research is needed to yield more information about the prevalence of PD, NES, and UFED.

After being included as an EDNOS in DSM-IV, BED was introduced as a specified and independent diagnostic category in DSM-5. Prevalence of BED was reported in several studies included in this review, and the prevalence of BED generally increased by increasing age in the reviewed studies. For example, Allen et al. [20] assessed BED among 1383 young Australian males and females at ages 14, 17, and 20. Point prevalence increased from 1.8% to 4.1% from age 14 to 20 (increase from 0.0% to 0.7% in males). Similarly, Stice et al. [17] investigated 496 young females (mean age 13 years at baseline), and reported a cumulative incidence of 2.7% and a lifetime prevalence at 3.0% by age 20. Finally, Trace et al. [6] assessed a larger and older sample of 13,295 females aged 20-47 years, with a reported lifetime prevalence of 5.8%. Prevalence of BED was generally higher among females than males across studies. A potential explanation for variability in BED prevalence rates is the inconsistent or lack of use of the DSM-5 marked distress criterion and binge eating specifiers such as guilt after binge eating [11].

### Impact of the DSM-5 on prevalence estimates
It is of interest to review whether the transition from DSM-IV to DSM-5 has yielded the intended alterations in reported prevalence, i.e. increased prevalence of AN

---

**Table 1 Overview of included studies published 2012-2017. Studies are grouped by design and listed in chronological order (Continued)**

| Author (Year) | N or (%) | Country | Gender (N or %) | Age range (mean and SD) | Sample | Assessment | Prevalence type | Prevalence (%) of ED, AN, BN (95% CI) | Prevalence (%) of BED, OSFED, UFED (95% CI) |
|---------------|----------|---------|----------------|-------------------------|--------|------------|----------------|--------------------------------------|------------------------------------------|
| Trace et al. [6] | 13,295 | Sweden | ♀ | 20-47 (mean and SD not available) | Twin registry subsample | An expanded SCID based instrument | Lifetime | BED: 1.6 (CI NR) | OSFED: 0.4 (CI NR) |
| **Note.** Prevalence rates are presented exactly as reported in their respective studies. ♀ = Females; ♂ = Males |
| **Abbreviations:** 95% CI = 95% Confidence Interval, NR = Not Reported, ED = Eating Disorders, AN = Anorexia Nervosa, ARFID = Avoidant Restrictive Food Intake Disorder, BN = Bulimia Nervosa, BED = Binge Eating Disorder, OSFED = Other Specified Eating and Eating Disorders, UFED = Unspecified Eating and Eating Disorders, L = Lifetime prevalence, P = Point prevalence, 12-m = 12-month prevalence, 3-m = 3-month prevalence |
| a = Prevalence rates are presented exactly as reported in their respective studies. |
| b = Prevalence rates are based on the same sample as in Mustelin et al. [7]. |
| c = Prevalence rates are based on observed cases. |
| d = Prevalence rates are based on the same sample as in Mustelin et al. [10]. |
| e = Prevalence rates originate from the Flament et al. [14] study. |
| f = Prevalence rates are presented exactly as reported in their respective studies. |
| g = Prevalence rates are presented exactly as reported in their respective studies. |
| h = Prevalence rates are presented exactly as reported in their respective studies. |
| i = Prevalence rates are presented exactly as reported in their respective studies. |
| j = Prevalence rates are presented exactly as reported in their respective studies. |
| k = Prevalence rates are presented exactly as reported in their respective studies. |
| l = Prevalence rates are presented exactly as reported in their respective studies. |
| m = Prevalence rates are presented exactly as reported in their respective studies. |
| n = Prevalence rates are presented exactly as reported in their respective studies. |
| o = Prevalence rates are presented exactly as reported in their respective studies. |
| p = Prevalence rates are presented exactly as reported in their respective studies. |
| q = Prevalence rates are presented exactly as reported in their respective studies. |
| r = Prevalence rates are presented exactly as reported in their respective studies. |
| s = Prevalence rates are presented exactly as reported in their respective studies. |
| t = Prevalence rates are presented exactly as reported in their respective studies. |
| u = Prevalence rates are presented exactly as reported in their respective studies. |
| v = Prevalence rates are presented exactly as reported in their respective studies. |
| w = Prevalence rates are presented exactly as reported in their respective studies. |
| x = Prevalence rates are presented exactly as reported in their respective studies. |
| y = Prevalence rates are presented exactly as reported in their respective studies. |
| z = Prevalence rates are presented exactly as reported in their respective studies. |
and BN, and decreased prevalence of the residual category EDNOS/OSFED. Several of the included studies in the present review have estimated prevalence of EDs as defined by both DSM-IV and DSM-5 in the same sample. Such recoding of diagnostic categories according to DSM-IV versus DSM-5 informs us on the impact of the DSM-5 on different ED prevalence rates. One study [7] assessed prevalence of AN by first adopting DSM-IV criteria. Subsequent to recoding according to the DSM-5 criteria, the authors observed a 60% increase in lifetime prevalence of AN among the 2825 female participants (mean age 24 years), from 2.2 to 3.6%. Another study recoding from DSM-IV to DSM-5 diagnoses investigated 1383 males (49%) and females at ages 14, 17, and 20 [20]. Significantly greater ED prevalence rates were reported when using DSM-5 criteria at all ages for females, and at age 17 only for males. These findings are in line with the study of Flamet et al. [13] reporting that prevalence of full-threshold EDs increased from 1.8 to 3.7% after recoding from DSM-IV to DSM-5 criteria. Decreased prevalence of the residual ED categories (EDNOS/OSFED) when adopting DSM-5 criteria have also been reported across studies having recoded ED diagnoses [9, 13, 20]. It is worth noting that although research recoding ED prevalence from DSM-IV to DSM-5 has been important in the initial evaluation of the proposed DSM-5 criteria, these studies may have missed patients who initially did not qualify for an ED diagnoses based on DSM-IV, but who would have met criteria for a DSM-5 ED. This may imply a risk of inaccurate prevalence estimates in these studies.

A main intention of the DSM-IV revisions was to minimize the use of catch-all diagnoses such as Eating Disorders Not Otherwise Specified (EDNOS), the most frequently, reported ED diagnosis in the DSM-IV. However, the revisions made may not only contribute to altered rates of AN, BN and OSFED diagnoses, but may also increase the likelihood of reaching the threshold for a formal ED diagnosis. As the new OSFED category includes disorders which lack strict diagnostic criteria (e.g. PD and NES which lacks frequency criteria), clinicians and researchers should be vigilant with regards to the characteristics, especially significant distress and impairments, separating eating disturbances from eating disorders.

Methodological aspects

Methodological aspects are likely to influence both lifetime- and point prevalence rates including assessment measures adopted and samples investigated [3]. The majority of studies in this review adopted self-report to assign ED diagnoses, followed by interviews and 2-stage designs. Although self-report assessments have its obvious advantages in terms of being cost- and time effective, only diagnostic interviews can help determine the presence (or absence) of a formal ED diagnosis as defined by the DSM. Methodological issues such as these should be considered when interpreting prevalence rates across studies. In addition to assessment measure per se, recruitment strategy and design are important aspects to consider when evaluating quality of studies and consequently reliability of results. The 2-stage design, including stage one with screening followed by stage two with clinical diagnostic interview, have been considered the preferred approach to estimate prevalence rates. In the current study, aiming to review the prevalence of diagnosable EDs as defined by the diagnostic manual DSM-5, it may therefore be timely to consider the included 2-stage design studies [7, 9, 10, 15, 16] to be among the highest ranked studies in terms of quality. However, another marker of quality in epidemiological studies is sample size. The reviewed studies with the largest sample sizes include samples of \(N = 6041\) [11], 13,295 [6], 10,038 [4], and 22,397 [27]. It is worth noting that none of these latter studies are among the mentioned 2-stage design studies, demonstrating the necessity to consider multiple methodological aspects when evaluating quality. In addition to the above-mentioned aspects, sample characteristics are likely to influence reported prevalence rates, and includes both age ranges and gender distributions. One of the intentions of the DSM-5 was to better capture EDs in males than during the DSM-IV era, and was a central rationale for removing the amenorrhea criteria for AN. However, as the DSM-5 revisions have contributed to higher prevalence of full-threshold AN and BN in general, it is difficult to detect whether the DSM-5 has led to better detection of male EDs per se. Also, although the amenorrhea criterion has been removed, the core ED psychopathology outlined in the DSM-5 is still biased towards females as it focuses on drive for thinness rather than muscularity. Furthermore, assessment measures used to detect ED psychopathology are often gender biased in that they have been developed to capture “female” psychopathology and symptoms, and also, as they most commonly are validated using female samples [28, 29]. Issues such as these may complicate the detection and description of ED pathology in males. Another methodological issue subsequent to the introduction of DSM-5 is the removal of a specific weight threshold for AN. This has clear advantages, maybe in particular in terms of individual and flexible evaluations in clinical settings, but it is worth noting that in research, the lack of an explicit weight criterion may lead to larger weight variations compared to earlier. In general, it is important to strive for consistent use of DSM-5 categories, which will aid the interpretation of prevalence rates across studies.
New diagnostic categories in the DSM-5 include ARFID (problem with eating not related to weight or shape concerns, leading to inability to take in adequate nutrition), pica (recurrent consumption of “nonnutritive, nonfood” items), and rumination disorder (RD; i.e. recurrent, effortless regurgitation of food). Although none of the included studies investigated these full-threshold diagnoses, three studies which were excluded due to their sub-threshold nature, addressed features of ARFID [30], pica and RD [31], reporting frequency numbers ranging from 0 to 3.2%. More research is needed to determine the prevalence of these diagnostic categories.

Finally, this review reports the prevalence of eating disorders according DSM-5 criteria. In a historical perspective there have been important changes to the diagnostic criteria since AN and BN were introduced in the DSM-III [32] in 1980. For example, in the DSM-III, the weight loss criteria for AN was “25% below original body weight”, which was then revised to “body weight less than 85% of that expected” in the DSM-IV [1], and subsequently, redefined in the DSM-5 [2] to “significantly low body weight”. For BN there were no criteria for frequency of binge eating and compensatory behavior in the DSM-III. With the DSM-III-R update, the frequency was specified to twice a week, and in DSM-5, it was reduced to once a week. These revisions will greatly influence prevalence rates in the years to come, and are crucial to address when comparing DSM-5 based prevalence to earlier epidemiological studies in EDs.

**Strengths and limitations**

This is the first systematic review of DSM-5 prevalence studies in EDs, and offers the reader an early snapshot of the extant prevalence literature. The core strength of the study is the thoroughness of the systematic literature review, and the detailed screening process conducted by two of the authors. Conversely, only one database was used to search the literature and only articles that were written in English (or had an available published English translation) were reviewed representing a limitation of the current study. Further, a meta-analysis was not performed which also represents a potential weakness. In addition, our search date (February 2017) dates our paper. In this interim, three publications relevant to the scope of our paper have been published. Hay et al. [33] investigated the prevalence and burden of ARFID and other DSM-5 EDs in an Australian population, Ernst et al. [34] explored how the DSM-5 revisions affected the prevalence, sex ratio and diagnostic distribution of EDNOS/OSFED in a student sample, and Micali et al. [35] investigated lifetime and 12-month prevalence of EDs amongst women in mid-life. Their relevance to the extant literature warrant a more detailed account in future epidemiological ED studies.

**Conclusions**

In conclusion, prevalence rates varied significantly across the 19 studies reviewed, much likely due to variations in study design, diagnostic assessment routines, samples sizes and characteristics. None of the included studies investigated the prevalence of the DSM-5 feeding disorders pica, ARFID and RD, warranting further investigation in future epidemiological studies. As our review is limited by a small number of studies published during a limited time frame, and in addition, fails to capture the full range of DSM-5 diagnoses, reported trends should be interpreted with caution.

**Abbreviations**

12-m: 12-month; 3-m: 3-month; AN: Anorexia nervosa; ARFID: Avoidant restrictive food intake disorder; BED: Binge eating disorder; BN: Bulimia nervosa; CI: Confidence interval; DSM-5: Diagnostic and statistical manual of mental disorders, fifth edition; DSM-IV: Diagnostic and statistical manual of mental disorders, fourth edition; ED: Eating disorder; EDE: Eating disorder examination; EDI-2: Eating disorder inventory; EDNOS: Eating disorder not otherwise specified; L: Lifetime; NEQ: Night eating questionnaire; NES: Night eating syndrome; NR: Not reported; OSFED: Other specified feeding and eating disorders; P: Purging disorder; PD: Purging disorder; SCID I-N/P: Structured clinical interview for DSM-IV-TR axis I disorders, research version, non-patient edition; SCID-I: Structured clinical interview for DSM-IV axis I disorders; SCOFF: Sick, control, one stone, fat, food questionnaire; SELCOH: South East London Community Health Study; UFED: Unspecified feeding and eating disorder; WHO-CIDI: World Health Organization Composite International Diagnostc Interview

**Acknowledgements**

Not applicable.

**Funding**

The work on this paper was supported by the Regional Department for Eating Disorders, Division of Mental Health and Addiction, Oslo University Hospital, Ullevål HF.

**Availability of data and materials**

All data generated or analyzed during this study are included in this published article [and its supplementary information files].

**Authors’ contributions**

CLD, LW and ØR conceived the study and initiated the study design. CLD, LW and ØR participated in the analysis and/or interpretation of data. CLD and LW drafted the manuscript, and all three authors revised it critically for important intellectual content. All three authors, CLD, LW and ØR, approved of the version of the manuscript to be published.

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1Regional Department for Eating Disorders, Division of Mental Health and Addiction, Oslo University Hospital, Ullevål HF, Postboks 4950 Nydalenv, 0424 Oslo, Norway. 2Institute of Clinical Medicine, University of Oslo, P.O. Box 1171 Blindern, 0318 Oslo, Norway.
